UY33541A - N-((6-amino-piridin-3-il)-metil)-heteroaril-carboxamidas - Google Patents
N-((6-amino-piridin-3-il)-metil)-heteroaril-carboxamidasInfo
- Publication number
- UY33541A UY33541A UY0001033541A UY33541A UY33541A UY 33541 A UY33541 A UY 33541A UY 0001033541 A UY0001033541 A UY 0001033541A UY 33541 A UY33541 A UY 33541A UY 33541 A UY33541 A UY 33541A
- Authority
- UY
- Uruguay
- Prior art keywords
- carboxamidas
- heteroaril
- piridin
- metil
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
La invención se refiere a un compuesto de la fórmula I en donde los sustituyentes son como se definen en la memoria descriptiva; en forma libre o en forma de sal; a su preparación, a su uso como un medicamento, y a medicamentos que lo comprenden.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37061210P | 2010-08-04 | 2010-08-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY33541A true UY33541A (es) | 2012-02-29 |
Family
ID=44503821
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001033541A UY33541A (es) | 2010-08-04 | 2011-08-02 | N-((6-amino-piridin-3-il)-metil)-heteroaril-carboxamidas |
Country Status (14)
Country | Link |
---|---|
US (1) | US9290485B2 (es) |
EP (1) | EP2601189B1 (es) |
JP (1) | JP5809267B2 (es) |
KR (1) | KR20130096253A (es) |
CN (1) | CN103080104B (es) |
AR (1) | AR082446A1 (es) |
AU (1) | AU2011287574B2 (es) |
CA (1) | CA2806015A1 (es) |
EA (1) | EA021359B1 (es) |
ES (1) | ES2542764T3 (es) |
MX (1) | MX2013001363A (es) |
TW (1) | TW201206900A (es) |
UY (1) | UY33541A (es) |
WO (1) | WO2012017020A1 (es) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2494851A (en) | 2011-07-07 | 2013-03-27 | Kalvista Pharmaceuticals Ltd | Plasma kallikrein inhibitors |
WO2013025858A1 (en) * | 2011-08-16 | 2013-02-21 | Glaxosmithkline Llc | 5-benzyl-n-phenyethyl-1,3,4-oxadiazole-2-carboxamide derivatives |
CN104245671B (zh) * | 2012-04-17 | 2017-03-22 | 富士胶片株式会社 | 含氮杂环化合物或其盐 |
GB201212081D0 (en) | 2012-07-06 | 2012-08-22 | Kalvista Pharmaceuticals Ltd | New polymorph |
GB201300304D0 (en) * | 2013-01-08 | 2013-02-20 | Kalvista Pharmaceuticals Ltd | Benzylamine derivatives |
IL239682B (en) | 2013-01-08 | 2018-10-31 | Kalvista Pharmaceuticals Ltd | History of benzylamine and 2-(aminomethyl)pyridine |
GB2510407A (en) | 2013-02-04 | 2014-08-06 | Kalvista Pharmaceuticals Ltd | Aqueous suspensions of kallikrein inhibitors for parenteral administration |
MY174018A (en) * | 2013-05-23 | 2020-03-04 | Kalvista Pharmaceuticals Ltd | Heterocyclic derivates |
US9198898B2 (en) | 2013-06-24 | 2015-12-01 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
US8906951B1 (en) | 2013-06-24 | 2014-12-09 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
GB2517908A (en) | 2013-08-14 | 2015-03-11 | Kalvista Pharmaceuticals Ltd | Bicyclic inhibitors |
EP3033336B1 (en) | 2013-08-14 | 2018-05-30 | Kalvista Pharmaceuticals Limited | Inhibitors of plasma kallikrein |
TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
KR101744033B1 (ko) | 2013-10-16 | 2017-06-07 | 후지필름 가부시키가이샤 | 함질소 복소환 화합물의 염 또는 그 결정, 의약 조성물 및 flt3 저해제 |
BR112016015449A8 (pt) * | 2013-12-30 | 2020-06-09 | Lifesci Pharmaceuticals Inc | compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos |
US9611252B2 (en) | 2013-12-30 | 2017-04-04 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
WO2016011209A1 (en) * | 2014-07-16 | 2016-01-21 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
JP6257782B2 (ja) | 2014-08-22 | 2018-01-10 | 富士フイルム株式会社 | Flt3変異陽性癌を処置するための医薬組成物、変異型flt3阻害剤およびそれらの応用 |
GB201421088D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
GB201421083D0 (en) * | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
JP6412471B2 (ja) | 2015-07-15 | 2018-10-24 | 富士フイルム株式会社 | 含窒素複素環化合物の製造方法およびその中間体 |
US10399961B2 (en) * | 2015-10-27 | 2019-09-03 | Boehringer Ingelheim International Gmbh | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
JP6855477B2 (ja) * | 2015-10-27 | 2021-04-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 血漿カリクレイン阻害薬としてのヘテロアリールカルボキサミド誘導体 |
TW202246215A (zh) | 2015-12-18 | 2022-12-01 | 美商亞德利克斯公司 | 作為非全身tgr5促效劑之經取代之4-苯基吡啶化合物 |
US10898469B2 (en) * | 2016-02-26 | 2021-01-26 | Sumitomo Dainippon Pharma Co., Ltd. | Imidazolylamide derivative |
RS60600B1 (sr) * | 2016-05-31 | 2020-08-31 | Kalvista Pharmaceuticals Ltd | Derivati pirazola kao inhibitori kalikreina plazme |
GB201609607D0 (en) * | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
WO2018011628A1 (en) | 2016-07-11 | 2018-01-18 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
CN106333949B (zh) * | 2016-07-28 | 2018-05-29 | 三峡大学 | 化合物在制备抑制激肽释放酶klk7的药物上的应用及其合成方法 |
CN106214681B (zh) * | 2016-07-28 | 2018-05-08 | 三峡大学 | 化合物在制备抑制激肽释放酶klk7的药物上的应用及其合成方法 |
TW201822637A (zh) | 2016-11-07 | 2018-07-01 | 德商拜耳廠股份有限公司 | 用於控制動物害蟲的經取代磺醯胺類 |
US11434472B2 (en) * | 2016-12-20 | 2022-09-06 | Sumitomo Pharma Co., Ltd. | Agent for removing undifferentiated iPS cells |
JP6775483B2 (ja) * | 2016-12-20 | 2020-10-28 | 大日本住友製薬株式会社 | 1,4−ジ置換イミダゾール誘導体からなる医薬 |
US11168080B2 (en) | 2017-04-26 | 2021-11-09 | Mitobridge, Inc. | Dynamin-1-like protein inhibitors |
PL3716952T3 (pl) * | 2017-11-29 | 2022-05-02 | Kalvista Pharmaceuticals Limited | Postacie dawkowania zawierające inhibitor kalikreiny osoczowej |
GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
GB201721515D0 (en) * | 2017-12-21 | 2018-02-07 | Kalvista Pharmaceuticals Ltd | Dosage forms comprising a plasma kallikrein inhibtor |
US11142536B2 (en) * | 2018-10-03 | 2021-10-12 | Massachusetts Institute Of Technology | Macromolecules comprising triazoles |
US11155527B2 (en) | 2018-10-03 | 2021-10-26 | Massachusetts Institute Of Technology | Macromolecules comprising triazoles and related compounds |
TW202031645A (zh) * | 2018-10-30 | 2020-09-01 | 丹麥商H 朗德貝克公司 | 作為Kv3鉀通道激活劑之芳基磺醯基吡咯甲醯胺衍生物 |
GB201910116D0 (en) | 2019-07-15 | 2019-08-28 | Kalvista Pharmaceuticals Ltd | Treatments of hereditary angioedema |
GB201910125D0 (en) | 2019-07-15 | 2019-08-28 | Kalvista Pharmaceuticals Ltd | Treatments of angioedema |
WO2021026672A1 (en) | 2019-08-09 | 2021-02-18 | Novartis Ag | Heterocyclic wdr5 inhibitors as anti-cancer compounds |
CN114206852A (zh) | 2019-08-09 | 2022-03-18 | 卡尔维斯塔制药有限公司 | 血浆激肽释放酶抑制剂 |
CR20220316A (es) | 2019-12-06 | 2022-10-07 | Vertex Pharma | Tetrahidrofuranos sustituidos como moduladores de canales de sodio |
GB2591730A (en) | 2019-12-09 | 2021-08-11 | Kalvista Pharmaceuticals Ltd | New polymorphs |
GB201918994D0 (en) | 2019-12-20 | 2020-02-05 | Kalvista Pharmaceuticals Ltd | Treatments of diabetic macular edema and impaired visual acuity |
EP4116299A4 (en) | 2020-03-04 | 2024-03-27 | Medshine Discovery Inc. | HETEROCYCLIC COMPOUND |
KR20230038526A (ko) * | 2020-07-10 | 2023-03-20 | 머크 샤프 앤드 돔 엘엘씨 | 혈장 칼리크레인 억제제 |
WO2022056051A1 (en) * | 2020-09-10 | 2022-03-17 | Merck Sharp & Dohme Corp. | Plasma kallikrein inhibitors |
WO2022079446A1 (en) | 2020-10-15 | 2022-04-21 | Kalvista Pharmaceuticals Limited | Treatments of angioedema |
US20230381162A1 (en) | 2020-10-23 | 2023-11-30 | Kalvista Pharmaceuticals Limited | Treatments of angioedema |
WO2022172006A1 (en) | 2021-02-09 | 2022-08-18 | Kalvista Pharmaceuticals Limited | Treatments of hereditary angioedema |
US11827627B2 (en) | 2021-06-04 | 2023-11-28 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
WO2023002219A1 (en) | 2021-07-23 | 2023-01-26 | Kalvista Pharmaceuticals Limited | Treatments of hereditary angioedema |
DK4288036T3 (da) | 2022-04-27 | 2024-08-26 | Kalvista Pharmaceuticals Ltd | Formuleringer af en plasmakallikreinhæmmer |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
US6664255B1 (en) * | 1999-05-19 | 2003-12-16 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade |
NZ520241A (en) | 2000-02-25 | 2004-05-28 | F | Adenosine receptor modulators |
AU2001255408A1 (en) | 2000-04-14 | 2001-10-30 | Corvas International, Inc. | Tetrahydro-azepinone derivatives as thrombin inhibitors |
AU2001273040A1 (en) | 2000-06-27 | 2002-01-08 | Du Pont Pharmaceuticals Company | Factor xa inhibitors |
AUPR649001A0 (en) | 2001-07-20 | 2001-08-09 | Holly, John Anthony | A precision seed and chemical placement implement |
FR2836143B1 (fr) * | 2002-02-21 | 2004-04-16 | Servier Lab | Nouveaux derives d'acides amines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
GB0205527D0 (en) | 2002-03-08 | 2002-04-24 | Ferring Bv | Inhibitors |
ATE479667T1 (de) | 2003-02-06 | 2010-09-15 | Bristol Myers Squibb Co | Als kinaseinhibitoren geeignete verbindungen auf thiazolylbasis |
CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
EP1678168B1 (en) | 2003-10-24 | 2012-07-11 | Exelixis, Inc. | P70s6 kinase modulators and method of use |
US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
US20080096932A1 (en) | 2004-07-23 | 2008-04-24 | Darren Mansfield | 3-Pyridinylethylcarboxamide Derivatives as Fungicides |
US7465809B2 (en) | 2004-11-16 | 2008-12-16 | Janssen Pharmaceutica N.V. | Heterocycle derivatives useful as selective androgen receptor modulators (SARMs) |
FR2885904B1 (fr) | 2005-05-19 | 2007-07-06 | Aventis Pharma Sa | Nouveaux derives du fluorene, compositions les contenant et utilisation |
WO2007000582A1 (en) | 2005-06-28 | 2007-01-04 | Takeda Cambridge Limited | Heterocyclic non-peptide gnrh antagonists |
AU2006325746A1 (en) | 2005-12-14 | 2007-06-21 | Bristol-Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
US7625944B2 (en) | 2006-07-31 | 2009-12-01 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
GB0807828D0 (en) | 2008-04-29 | 2008-06-04 | Vantia Ltd | Aminopyridine derivatives |
WO2010078408A1 (en) | 2008-12-30 | 2010-07-08 | Biogen Idec Ma Inc. | Heteroaryl compounds useful as raf kinase inhibitors |
US8969342B2 (en) | 2009-03-20 | 2015-03-03 | Brandeis University | Compounds and methods for treating mammalian gastrointestinal microbial infections |
US8946231B2 (en) | 2009-03-23 | 2015-02-03 | Merck Sharp & Dohme Corp. | P2X3, receptor antagonists for treatment of pain |
MX2011012712A (es) | 2009-05-29 | 2012-01-30 | Raqualia Pharma Inc | Derivados de carboxamida sustituidos con arilo como bloqueadores del canal de calcio o sodio. |
EA201200218A1 (ru) | 2009-08-06 | 2012-09-28 | Мерк Патент Гмбх | Новые бициклические соединения мочевины |
GB0918922D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminopyridine derivatives |
GB0918923D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminothiazole derivatives |
GB0918924D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Azaindole derivatives |
SG181811A1 (en) | 2009-12-18 | 2012-07-30 | Activesite Pharmaceuticals Inc | Prodrugs of inhibitors of plasma kallikrein |
-
2011
- 2011-07-29 US US13/194,009 patent/US9290485B2/en not_active Expired - Fee Related
- 2011-08-02 UY UY0001033541A patent/UY33541A/es not_active Application Discontinuation
- 2011-08-02 AR ARP110102785A patent/AR082446A1/es unknown
- 2011-08-03 WO PCT/EP2011/063389 patent/WO2012017020A1/en active Application Filing
- 2011-08-03 TW TW100127620A patent/TW201206900A/zh unknown
- 2011-08-03 MX MX2013001363A patent/MX2013001363A/es not_active Application Discontinuation
- 2011-08-03 EP EP11745519.6A patent/EP2601189B1/en not_active Not-in-force
- 2011-08-03 CN CN201180041505.7A patent/CN103080104B/zh not_active Expired - Fee Related
- 2011-08-03 KR KR1020137005250A patent/KR20130096253A/ko not_active Application Discontinuation
- 2011-08-03 AU AU2011287574A patent/AU2011287574B2/en not_active Ceased
- 2011-08-03 JP JP2013522243A patent/JP5809267B2/ja not_active Expired - Fee Related
- 2011-08-03 EA EA201300200A patent/EA021359B1/ru not_active IP Right Cessation
- 2011-08-03 CA CA2806015A patent/CA2806015A1/en not_active Abandoned
- 2011-08-03 ES ES11745519.6T patent/ES2542764T3/es active Active
Also Published As
Publication number | Publication date |
---|---|
CN103080104B (zh) | 2015-04-08 |
JP2013532713A (ja) | 2013-08-19 |
EA201300200A1 (ru) | 2013-06-28 |
AR082446A1 (es) | 2012-12-05 |
AU2011287574A1 (en) | 2013-02-28 |
CN103080104A (zh) | 2013-05-01 |
EP2601189A1 (en) | 2013-06-12 |
US9290485B2 (en) | 2016-03-22 |
EP2601189B1 (en) | 2015-04-15 |
TW201206900A (en) | 2012-02-16 |
JP5809267B2 (ja) | 2015-11-10 |
EA021359B1 (ru) | 2015-05-29 |
US20120035168A1 (en) | 2012-02-09 |
CA2806015A1 (en) | 2012-02-09 |
WO2012017020A1 (en) | 2012-02-09 |
KR20130096253A (ko) | 2013-08-29 |
ES2542764T3 (es) | 2015-08-11 |
MX2013001363A (es) | 2013-02-21 |
AU2011287574B2 (en) | 2015-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY33541A (es) | N-((6-amino-piridin-3-il)-metil)-heteroaril-carboxamidas | |
UA108101C2 (xx) | Похідні n3-заміщених n1-сульфоніл-5-фторпіримідинонів | |
UY32404A (es) | 4-aril-butan-1,3-diamidas | |
CR20210079A (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
ECSP14027269A (es) | Picolinamidas macrocíclicas como fungicidas | |
EA201270254A1 (ru) | Производные 5-фторпиримидинона | |
EA201270257A1 (ru) | Производные n1-сульфонил-5-фторпиримидинона | |
TR201911139T4 (tr) | Sitotoksik ve anti-mitotik bileşikler ve bunları kullanmanın yöntemleri. | |
EA201591624A1 (ru) | Новые производные пиразола | |
EA201590296A1 (ru) | Дейтерированный ибрутиниб | |
EA201300388A1 (ru) | Соединения замещенного бензамида | |
CR20150171A (es) | Benzamidas | |
CU20150061A7 (es) | PIRIMIDO-[4,5-b]-QUINOLINA-4,5(3H,10H)-DIONAS COMO SUPRESORAS DE MUTACIÓN SIN SENTIDO | |
CO7170173A2 (es) | Derivados de carbamato/urea | |
DOP2013000307A (es) | Antagonistas de trpv4 | |
TR201908180T4 (tr) | N1-asil- 5-floropirimidinon deriveleri. | |
TR201903918T4 (tr) | Bir dağıtım ajanı içeren bileşimler ve bunların hazırlanması. | |
ECSP16096831A (es) | Derivados de naftiridinadiona | |
BR112015026048A2 (pt) | análogos de combretastatina | |
UY34986A (es) | Derivados de diazepinona | |
EA201500313A1 (ru) | Стабилизированная аморфная форма агомелатина, способ ее изготовления и фармацевтические композиции, ее содержащие | |
EA201690593A1 (ru) | Новые соединения мочевины | |
MA37778A1 (fr) | Dérivés de carbamate/urée | |
TR201910829T4 (tr) | Piripiropen bileşiği hazırlama metodu. | |
UY33399A (es) | Nuevas amidas ácidas, su preparación y uso como fungicidas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20200820 |